evaluate the pharmaceuticals company byetta on semaglutide for weight loss A new study from University of Georgia put popular GLP-1 medications head-to-head, testing which one is the most effective loss. https://www.cbs42.com/news/health/which-glp-1-works-best-new-meta-study-puts-them-head-to-head/?utm_medium Acute Care

In a nutshell While the idea of Ozempic-style weight-loss patches might seem appealing, they do not work, and their safety is far from guaranteed

Eli Lilly stated "Lilly is deeply concerned that products fraudulently claimed by compounding pharmacies or counterfeiters to be FDA-approved tirzepatide, Mounjaro, or Zepbound may expose patients to serious health risks." Novo Nordisk said its lawsuits "aim to protect US patients and consumers from deceptive marketing by these entities as well as potentially harmful and improperly compounded drugs claiming to contain semaglutide." At least seven deaths linked to compounded versions of semaglutide, the active ingredient in these medications, have been reported to the FDA

Grunvald says the same missteps tend to come up again and again, including not confirming that prior authorization is needed for coverage, not seeking out obesity medicine-certified professionals if their regular provider does not have the experience to navigate these challenges, and not using savings cards for cost savings. Pharmacies need to be looped in, too

Current scientific investigations focus on metabolic regulation, receptor signalling, energy metabolism, peptide pharmacology, and molecular pathway modelling under controlled laboratory conditions